Flower City Capital Outlook Therapeutics, Inc. Transaction History

Flower City Capital

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 10, 2023	SELL	$0.2 - $1.78 $4,000 - $35,600	-20,000 Reduced 40.0%	30,000 $6,000
Q2 2023 Jul 24, 2023	SELL	$1.02 - $1.89 $4,090 - $7,578	-4,010 Reduced 7.42%	50,000 $87,000
Q4 2022 Jan 11, 2023	BUY	$0.87 - $1.33 $1,941 - $2,968	2,232 Added 4.31%	54,010 $0
Q2 2022 Jul 12, 2022	BUY	$0.91 - $2.01 $28,917 - $63,873	31,778 Added 158.89%	51,778 $53,000
Q1 2022 Apr 14, 2022	BUY	$1.22 - $2.03 $24,400 - $40,599	20,000 New	20,000 $36,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $536M
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Flower City Capital, based on Form 13F filings with the SEC.

Stay updated on Flower City Capital with notifications on news.